EUVIMEDEUVIMED entdecken
Netzwerk-Metaanalyse

Efficacy and Safety of Biologics, Allergen Immunotherapy, and Pharmacotherapies for Moderate‐to‐Severe Allergic Rhinitis: A Network Meta‐Analysis

Zengxiao Zhang iD, Dandan Fang, Chengshuo Wang, Yuan Zhang iD, Luo Zhang iD

International Forum of Allergy & Rhinology · 2026

DOI: 10.1002/alr.70108 ↗

Kurz gefasst

Netzwerk-Metaanalyse in der Zeitschrift International Forum of Allergy & Rhinology, 2026. Verfasst von Zengxiao Zhang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Allergy, Beijing Tongren Hospital, Capital Medical University, Beijing, China. Hauptthemen laut MEDLINE: Desensitization, Immunologic, Biological Products, Rhinitis, Allergic, Anti-Allergic Agents. Die Arbeit nennt 59 Literaturangaben. Gefördert von: Beijing Hospitals Authority Clinical Medicine Development of Special Funding, National Key Research and Development Program of China, Program for the Changjiang Scholars and Innovative Research Team.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The management of moderate‐to‐severe allergic rhinitis (AR) is challenging given numerous advanced therapies. A comparative, evidence‐based treatment hierarchy to guide the selection of biologics, allergen immunotherapy (AIT), and advanced pharmacotherapies is critically lacking due to a paucity of head‐to‐head trials. This network meta‐analysis established a treatment hierarchy for moderate‐to‐severe AR by comparing the efficacy and safety of biologics, AIT, and key pharmacotherapies.

Methods

We analyzed 28 randomized controlled trials (13,312 participants), which evaluated the efficacy and safety of biologics (anti‐IgE, anti‐IL‐4Rα therapies), AIT (evaluated within a 6‐month time frame to ensure comparability), and key pharmacotherapies (intranasal corticosteroids alone or combined with antihistamines) for moderate‐to‐severe AR. Efficacy was assessed by changes in the Total Nasal Symptom Score (TNSS), the Total Ocular Symptom Score (TOSS), and the Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ). A treatment hierarchy was established using surface under the cumulative ranking curve (SUCRA) probabilities.

Results

For the TNSS, anti‐IL‐4Rα therapy was most effective, followed by anti‐IgE therapy and AIT, which surpassed all pharmacotherapies. The combination of intranasal corticosteroid and intranasal antihistamine ranked the highest for ocular symptoms. Anti‐IL‐4Rα therapy was also superior for improving the RQLQ. Overall, all treatments demonstrated a favorable safety profile. Biologics and AIT did not show a significant increase in adverse events risk compared to placebo.

Conclusions

This network meta‐analysis establishes the first comprehensive treatment hierarchy for moderate‐to‐severe AR. Our findings demonstrate that biologics, particularly anti‐IL‐4Rα therapy, are the most effective interventions for nasal symptom control, ranking superior to AIT and pharmacotherapies, thus providing a robust, data‐driven framework to personalize patient care.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Desensitization, ImmunologicBiological ProductsRhinitis, AllergicAnti-Allergic AgentsHumansTreatment OutcomeRandomized Controlled Trials as TopicAdrenal Cortex HormonesHistamine AntagonistsSeverity of Illness Index

Stichwörter der Autor:innen

allergen immunotherapyallergic rhinitisbiologicsnetwork meta‐analysistreatment hierarchy

Substanzen

Biological ProductsAnti-Allergic AgentsAdrenal Cortex HormonesHistamine Antagonists

Autor:innen und Institutionen

  • Department of Allergy, Beijing Tongren Hospital, Capital Medical University, Beijing, China.
  • Department of Otolaryngology Head and Neck Surgery, Beijing Tongren Hospital, Capital Medical University, Beijing, China.
  • Beijing Laboratory of Allergic Diseases and Beijing Key Laboratory of Nasal Diseases, Beijing Institute of Otolaryngology, Beijing, China.
  • Laboratory for Clinical Medicine, Capital Medical University, Beijing, China.

ORCID-Profile: Zengxiao Zhang, Yuan Zhang, Luo Zhang

Förderung

  • Beijing Hospitals Authority Clinical Medicine Development of Special Funding
  • National Key Research and Development Program of China
  • Program for the Changjiang Scholars and Innovative Research Team
  • Natural Science Foundation of China
  • National Natural Science Foundation of China

Zitieren

APA

Zhang, Z., Fang, D., Wang, C., Zhang, Y., & Zhang, L. (2026). Efficacy and Safety of Biologics, Allergen Immunotherapy, and Pharmacotherapies for Moderate‐to‐Severe Allergic Rhinitis: A Network Meta‐Analysis. International Forum of Allergy & Rhinology. https://doi.org/10.1002/alr.70108

Vancouver

Zhang Z, Fang D, Wang C, Zhang Y, Zhang L. Efficacy and Safety of Biologics, Allergen Immunotherapy, and Pharmacotherapies for Moderate‐to‐Severe Allergic Rhinitis: A Network Meta‐Analysis. International Forum of Allergy & Rhinology. 2026. doi:10.1002/alr.70108

BibTeX
@article{Zhang2026,
  author = {Zhang, Zengxiao and Fang, Dandan and Wang, Chengshuo and Zhang, Yuan and Zhang, Luo},
  title = {Efficacy and Safety of Biologics, Allergen Immunotherapy, and Pharmacotherapies for Moderate‐to‐Severe Allergic Rhinitis: A Network Meta‐Analysis},
  journal = {International Forum of Allergy & Rhinology},
  year = {2026},
  doi = {10.1002/alr.70108}
}
Kostenlos starten →